ARTES Biotechnology announce expansion of the management board
Volker Jenzelewski reinforces the executive board of ARTES Biotechnology
(PresseBox) - ARTES Biotechnology GmbH announced today that Volker Jenzelewski reinforces the executive board of ARTES as Managing Director beginning of the year. He will manage the company in close cooperation with Dr. Michael Piontek, Managing Director and founder of ARTES Biotechnology and with Dr. Melanie Piontek, Business Development Director.
Volker Jenzelewski started his career at Rhein Biotech GmbH in 1993 after graduating in biology. In positions of increasing responsibility in technical management and GMP manufacturing, Mr. Jenzelewski eventually became Director of Process Development and Head of Manufacturing at Dynavax Europe. His final responsibility was the validation of antigen production and the support of regulatory filings for HEPLISAV-B®, the lead product of Dynavax Technologies Corporation. In the years 2010 to 2013, Mr. Jenzelewski was Managing Director of EUFETS GmbH, a CDMO in the field of advanced therapy medicinal products and a BioNTech subsidiary. He advanced the operative integration of EUFETS and the expansion into mRNA manufacturing.
He joined ARTES Biotechnology GmbH in 2014 as Director of Technology, steering the company´s development and technology transfer activities and providing technical review for business decisions.
With the expansion of the management board by Volker Jenzelewski, ARTES Biotechnology strengthens its position as a first-class solution provider and expands its future activities.
ARTES Biotechnology GmbH is a German company specialized in the development of processes for the production of recombinant proteins from microbial expression systems. In particular, the company offers the development of optimized production cell lines and processes based on yeast (Hansenula, Pichia, Saccharomyces) and bacteria (E. coli). The expression platform is complemented by a unique virus-like particle (VLP) technology for antigen presentation and vaccine development. For more than 20 years, ARTES has successfully partnered with human and animal health companies, enzyme manufacturers, and the cosmetics, diagnostics, and nutrition industries. The company operates worldwide from its 945 sqm facility in Langenfeld, Germany.
Unternehmensinformation / Kurzprofil:
ARTES Biotechnology GmbH is a German company specialized in the development of processes for the production of recombinant proteins from microbial expression systems. In particular, the company offers the development of optimized production cell lines and processes based on yeast (Hansenula, Pichia, Saccharomyces) and bacteria (E. coli). The expression platform is complemented by a unique virus-like particle (VLP) technology for antigen presentation and vaccine development. For more than 20 years, ARTES has successfully partnered with human and animal health companies, enzyme manufacturers, and the cosmetics, diagnostics, and nutrition industries. The company operates worldwide from its 945 sqm facility in Langenfeld, Germany.
Datum: 10.01.2024 - 13:13 Uhr
Sprache: Deutsch
News-ID 698133
Anzahl Zeichen: 2340
contact information:
Contact person: Dr. Melanie Piontek
Town:
Langenfeld
Phone: +49 (2173) 2758712
Kategorie:
Handcrafts
Diese Pressemitteilung wurde bisher 706 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"ARTES Biotechnology announce expansion of the management board"
steht unter der journalistisch-redaktionellen Verantwortung von
ARTES Biotechnology GmbH (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
